View on Pubmed.gov 36892034 | View on doi.org 10.1177/1073858...
Tau, RNA, and RNA-Binding Proteins: Complex Interactions in Health and Neurodegenerative Diseases.
- Department of Biochemistry, University of Colorado Boulder, Boulder, CO, USA.
- Medical Scientist Training Program, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
- Howard Hughes Medical Institute, University of Colorado, Boulder, CO, USA.
Abstract
The tau protein is a key contributor to multiple neurodegenerative diseases. The pathology of tau is thought to be related to tau's propensity to form self-templating fibrillar structures that allow tau fibers to propagate in the brain by prion-like mechanisms. Unresolved issues with respect to tau pathology are how the normal function of tau and its misregulation contribute to disease, how cofactors and cellular organelles influence the initiation and propagation of tau fibers, and determining the mechanism of tau toxicity. Herein, we review the connection between tau and degenerative diseases, the basis for tau fibrilization, and how that process interacts with cellular molecules and organelles. One emerging theme is that tau interacts with RNA and RNA-binding proteins, normally and in pathologic aggregates, which may provide insight into alterations in RNA regulation observed in disease.
References
Cited by 5 citations (total)
Journal Article Review
Navigating Alzheimer's Disease Mouse Models: Age-Related Pathology and Cognitive Deficits.
Electronic publication date November 27, 2024
Laura Maria De Plano [...] Antonella Caccamo et al.
Since the mid-1990s, scientists have been generating mouse models of Alzheimer's disease to elucidate key mechanisms underlying the onset and...
Journal Article
Pathogenic oligomeric Tau alters neuronal RNA processes through the formation of nuclear heteromeric amyloids with RNA-binding protein Musashi1.
Electronic publication date March 21, 2025
Nicha Puangmalai [...] Mauro Montalbano et al.
Alzheimer's disease (AD) is marked by cytoplasmic proteinopathies, primarily involving misfolded Tau protein. Pathogenic Tau species, such as soluble oligomers...
Conflict of interest statement
Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: R.P. is a founder and consultant for Faze Medicines.
MeSH
- •
- •
- •
- •
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
- •
- •
Substances
- •
- •